Archive: January 06 2021

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Immunotherapy Web Featured Images 86

Interim results from ZUMA-12: Axi-cel as frontline treatment for high-risk LBCL

Patients with high-risk large B-cell lymphoma (LBCL) are mainly treated with rituximab-based chemoimmunotherapies that do not provide sufficient efficacy, as approximately 50% of these patients will not achieve long-term disease remission.

Visit website